Avicanna

Avicanna is a commercial-stage international biopharmaceutical company focused on the development, manufacturing, and commercialization of evidence-based cannabinoid-based products. The company has an established scientific platform encompassing research and development along with clinical trials. This has enabled the commercialization of over thirty products across various market segments.

Avicanna offers a diverse range of proprietary medical cannabis and wellness products under the RHO Phyto brand. These include oral, sublingual, topical, and transdermal formulations with varying ratios of cannabinoids like CBD, CBG, and THC. The formulary is supported by ongoing patient and medical community education initiatives. RHO Phyto has emerged as a leading medical brand in Canada, available nationwide through several medical channels, and is expanding into new international markets.

The company's pharmaceutical pipeline leverages its scientific platform, vertical integration, and real-world evidence. Avicanna has developed a pipeline of patent-pending drug candidates tailored for specific medical indications at various stages of clinical development and commercialization. These cannabinoid-based drug candidates aim to address unmet medical needs in areas such as dermatology, chronic pain, and neurological disorders. Avicanna's first pharmaceutical preparation, Trunerox, is in the drug registration stage in South America.

In February 2024, Avicanna secured an exclusive supply agreement with a multinational pharmaceutical company for two of its proprietary topical products in the European region, along with a right of first refusal agreement for its SEDDS capsules in the same region.

In January 2024, Avicanna's full-spectrum API received commercialization approval from ANVISA for a pharmaceutical preparation produced in Brazil by Ease Labs Pharma, containing 2.5% CBD and up to 0.2% THC.